🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Viral Infection of HSPC Impacts Hematopoiesis

Recruitingn/aAges 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
NCT06458504 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: HIV patients : * HIV-positive patients with a negative or positive viral load. * managed at Ambroise Paré Hospital. * patients with a bone marrow biopsy or myelogram performed as part of their care. Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology. Management at Ambroise Paré Hospital. Exclusion Criteria: \-
💊

What it tests

  • Not listed
📍

Where

1 site
Hematology and interne medicine department, Ambroise Paré hospital - APHP
Boulogne-Billancourt, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy